RDP-58 (SangStat Medical).
RDP-58, a decapeptide with inhibitory effects on tumor necrosis factor synthesis, is under development by SangStat Medical Corp for the potential treatment of Crohn's disease and ulcerative colitis; phase II trials for both these indications commenced in October 2001. SangStat also initiated a phase I trial in chemotherapy-induced diarrhea in the first quarter of 2003 and anticipates initiating phase I trials in the gastrointestinal complications of HIV by the end of 2003.